Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
04/2003
04/08/2003US6544991 Compositions and methods for treating bacterial infections
04/08/2003US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
04/08/2003US6544568 Symbiotic functional food containing lactic acid bacteria
04/08/2003US6544544 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule
04/08/2003US6544510 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
04/08/2003US6544509 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
04/08/2003US6544508 Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799)
04/08/2003US6544498 Passing milk or milk-derived ingredient through a cation-exchange resin, and eluting; isoelectric point of 7.5-11; food/drink, toothpaste and gargling agents
04/08/2003CA2096833C Method for preparing taxane derivatives, novel derivatives thereby obtained and pharmaceutical compositions containing same
04/08/2003CA2062271C Derivatives of substituted imidazol-2-one and process for their preparation
04/08/2003CA2049212C 6-substituted-tetrahydrobenz ¬cd| indoles
04/07/2003WO2002032866A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
04/03/2003WO2003027637A2 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027234A2 Small organic molecule regulators of cell proliferation
04/03/2003WO2003027228A2 Receptors and membrane-associated proteins
04/03/2003WO2003027146A1 Use of cardiotrophin in hepatic diseases
04/03/2003WO2003027111A1 Chemical compounds
04/03/2003WO2003027102A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003027098A1 Benzimidazole compound, process for producing the same, and use thereof
04/03/2003WO2003027090A2 Bicyclic heterocycles as rxr ligands
04/03/2003WO2003027077A1 Water-soluble phenylpyridazine derivatives and drugs containing the same
04/03/2003WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027060A1 Diphenylbutane amide derivatives
04/03/2003WO2003026743A2 Opioid formulations having reduced potential for abuse
04/03/2003WO2003026685A1 Agents improving lipid metabolism in liver
04/03/2003WO2003026683A1 Health caring product for enhancing immunity and delaying aging
04/03/2003WO2003026670A2 Method for inhibiting the proliferation of hepatic stellate cells with a ligand of the low affinity glucocorticoid binding site (lags)
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026660A1 An enantiomerically pure diarylmethylpiperazine and methods of using same
04/03/2003WO2003026659A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003WO2003026656A1 New formulations and use thereof
04/03/2003WO2003026655A1 New formulations and use thereof
04/03/2003WO2003026651A1 Method of inhibiting the production and/or effects of intestinal pro-inflammatory cytokines, prostaglandins and others
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026589A2 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003011395A3 Method of utilizing neurotrophins to manipulate reproductive capacity
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002102305A3 Adjuvant composition for mucosal and injection delivered vaccines
04/03/2003WO2002094270A3 Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002092049A3 System for delivering cosmetics and pharmaceuticals
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002089729A3 Fused heterocyclic compounds
04/03/2003WO2002085312A3 Process for purifying 6-methoxy omeprazole
04/03/2003WO2002074738A3 Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage)
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002032414A3 Ribavirin-pegylated interferon alfa hcv combination therapy
04/03/2003WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
04/03/2003WO2002000860A3 Novel proteases
04/03/2003US20030065195 Ether compounds
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065173 Therapy for drug abuse
04/03/2003US20030065146 Compound for use in the treatment of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and sepsis
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065018 Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064999 Therapy for asthma, diarrhea
04/03/2003US20030064993 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064983 Headaches; antiarthritic agents; respiratory system disorders; psychological disorders
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064369 Novel proteins and nucleic acids encoding same
04/03/2003US20030064102 Antimicrobial Composition
04/03/2003US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003US20030064088 Surgically implantable and sealable drug delivery device that upon contact of its contents via an interface window or port with an organ or tissue exposes a therapeutic agent to organ or tissue surface, allowing a controlled, selective diffusion
04/03/2003US20030064085 Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent
04/03/2003US20030064036 Coating and binding agent for pharmaceutical formulations with improved storage stability
04/03/2003CA2688860A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003CA2461806A1 Water-soluble phenylpyridazine derivatives and medicines containing the same
04/03/2003CA2461709A1 Small organic molecule regulators of cell proliferation
04/03/2003CA2461666A1 Combination therapies for immune mediated diseases
04/03/2003CA2461454A1 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
04/03/2003CA2461357A1 Method for inhibiting the proliferation of hepatic stellate cells with a ligand of the low affinity glucocorticoid binding site (lags)
04/03/2003CA2461095A1 Process for making substituted pyrazoles
04/03/2003CA2461007A1 Use of cardiotrophin in liver diseases
04/03/2003CA2460953A1 Proteins associated with cell growth, differentiation, and death
04/03/2003CA2459976A1 Opioid formulations having reduced potential for abuse
04/03/2003CA2459943A1 Androstanes as androgen receptor modulators
04/03/2003CA2453985A1 Receptors and membrane-associated proteins
04/02/2003WO2002028821A2 Propionic acid derivatives with ppar-alpha activating properties
04/02/2003EP1298348A1 Bush, group of bush, suspension cross-member, vehicle, method for mounting a bush and method for mounting a group of bushes
04/02/2003EP1298208A2 Ribozymes targeting a hiv tat sequence
04/02/2003EP1298206A1 Use of the Factor VII-activating protease for prevention and therapy of vaso-proliferative disorders
04/02/2003EP1297836A1 COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED
04/02/2003EP1297180A2 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
04/02/2003EP1297152A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof
04/02/2003EP1297142A2 Dual specificity antibodies and methods of making and using
04/02/2003EP1297133A2 Gp354 nucleic acids and polypeptides
04/02/2003EP1297130A2 G-protein coupled receptors
1 ... 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 ... 1258